CLEO Diagnostics (ASX:COV) has revealed it’s kicked off US-based trials sussing the reliability of its blood tests designed to detect ovarian cancer. Eight recruitment centres in the US are involved with the tests specifically looking at the efficacy of Cleo’s tests in the US market. Ideally, the company will kick off an FDA application next year on the back of the trial datum. The trial is notably large in scope, with the company hoping to amass no less than 500 patients to take part with a best-as-possible sample representation of the US population – recruitment is taking place in six differ…